Cognition Therapeutics Stock Today
| CGTX Stock | USD 0.45 0.02 4.65% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Cognition Therapeutics is trading at 0.45 as of the 22nd of March 2025; that is 4.65 percent increase since the beginning of the trading day. The stock's open price was 0.43. Cognition Therapeutics has about a 27 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of October 2021 | Category Healthcare | Classification Health Care |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Cognition Therapeutics, Inc. The company has 41.55 M outstanding shares of which 222.75 K shares are currently shorted by private and institutional investors with about 0.8 trading days to cover. More on Cognition Therapeutics
Moving together with Cognition Stock
Moving against Cognition Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cognition Stock Highlights
| President CEO | Lisa Ricciardi | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCognition Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cognition Therapeutics' financial leverage. It provides some insight into what part of Cognition Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cognition Therapeutics (CGTX) is traded on NASDAQ Exchange in USA. It is located in 2500 Westchester Ave., Purchase, NY, United States, 10577 and employs 25 people. Cognition Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.73 M. Cognition Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 41.55 M outstanding shares of which 222.75 K shares are currently shorted by private and institutional investors with about 0.8 trading days to cover.
Cognition Therapeutics currently holds about 46.61 M in cash with (28.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cognition Therapeutics Probability Of Bankruptcy
Ownership AllocationCognition Therapeutics holds a total of 41.55 Million outstanding shares. Cognition Therapeutics shows 3.34 percent of its outstanding shares held by insiders and 26.69 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cognition Ownership Details
Cognition Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2024-12-31 | 91.1 K | |
| Commonwealth Equity Services Inc | 2024-12-31 | 90.7 K | |
| Virtu Financial Llc | 2024-12-31 | 80.2 K | |
| Two Sigma Investments Llc | 2024-12-31 | 53.7 K | |
| Fca Corp | 2024-12-31 | 51.5 K | |
| Circle Wealth Management, Llc | 2024-12-31 | 48.8 K | |
| Northern Trust Corp | 2024-12-31 | 47.5 K | |
| Castle Wealth Management Llc | 2024-12-31 | 43.4 K | |
| Ubs Group Ag | 2024-12-31 | 41.1 K | |
| Bios Capital Management, Lp | 2024-12-31 | 6 M | |
| Vanguard Group Inc | 2024-12-31 | 1.2 M |
Cognition Therapeutics Historical Income Statement
Cognition Stock Against Markets
Cognition Therapeutics Corporate Management
| Steven Weissman | VP CMC | Profile | |
| Bobby Horn | Corporate Controller | Profile | |
| Andrew CPA | Interim Officer | Profile | |
| John Doyle | Chief Officer | Profile | |
| Anita Cornet | Head Quality | Profile |
Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.